Sarepta gets narrow ‘yes’ vote on Duchenne gene therapy in key FDA committee hearing

A committee of expert advisers to the U.S. Food and Drug Administration voted eight to six in favor of giving a Duchenne muscular dystrophy drug made by Sarepta Therapeutics Inc. accelerated approval in a key meeting.